Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N A Helsby

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
British Journal of Clinical Pharmacology|October 1, 1990
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolismN A Helsby, S A Ward, G Edwards, et al.
British Journal of Clinical Pharmacology|June 21, 2019
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesN A Helsby, M Yong, M van Kan, et al.
British Journal of Cancer|March 5, 2004
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPTN A Helsby, D M Ferry, A V Patterson, et al.
Acta Dermato-Venereologica|April 16, 1998
Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compoundN A Helsby, S A Ward, R A Parslew, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2015
High CYP2C19 phenotypic variability in gastrointestinal cancer patientsK E Burns, W-Y Lo, M P Findlay, et al.
British Journal of Clinical Pharmacology|June 1, 1991
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyS A Ward, N A Helsby, E Skjelbo, et al.
British Journal of Cancer|October 16, 2008
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeN A Helsby, W-Y Lo, K Sharples, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 9, 1999
Interleukin-4 differentially regulates prostaglandin production in amnion-derived WISH cells stimulated with pro-inflammatory cytokines and epidermal growth factorJ A Keelan, T A Sato, W R Hansen, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 27, 2014
The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agentsM R Bull, J A Spicer, K M Huttunen, et al.
British Journal of Pharmacology|October 20, 2010
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liverM Dogra, B D Palmer, G Bashiri, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
British Journal of Clinical Pharmacology|October 1, 1990
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolismN A Helsby, S A Ward, G Edwards, et al.
British Journal of Clinical Pharmacology|June 21, 2019
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesN A Helsby, M Yong, M van Kan, et al.
British Journal of Cancer|March 5, 2004
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPTN A Helsby, D M Ferry, A V Patterson, et al.
Acta Dermato-Venereologica|April 16, 1998
Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compoundN A Helsby, S A Ward, R A Parslew, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2015
High CYP2C19 phenotypic variability in gastrointestinal cancer patientsK E Burns, W-Y Lo, M P Findlay, et al.
British Journal of Clinical Pharmacology|June 1, 1991
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyS A Ward, N A Helsby, E Skjelbo, et al.
British Journal of Cancer|October 16, 2008
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeN A Helsby, W-Y Lo, K Sharples, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 9, 1999
Interleukin-4 differentially regulates prostaglandin production in amnion-derived WISH cells stimulated with pro-inflammatory cytokines and epidermal growth factorJ A Keelan, T A Sato, W R Hansen, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 27, 2014
The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agentsM R Bull, J A Spicer, K M Huttunen, et al.
British Journal of Pharmacology|October 20, 2010
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liverM Dogra, B D Palmer, G Bashiri, et al.
Pageof 2